肿瘤药代表-江西区域

四川百利天恒药业股份有限公司

Chinese pharmaceutical group headquartered in Chengdu, Sichuan and listed on the Shanghai STAR Market under code 688506, tracing back to Baili Pharmaceutical founded in 1996 by chairman, chief executive and chief scientific officer Dr Zhu Yi. Combines end-to-end early research, clinical development, manufacturing and commercialisation, with globally competitive innovation in large molecule cancer therapy across antibody-drug conjugates, GNC multispecific antibodies and antibody-radionuclide conjugates alongside a generics business holding more than a hundred production approvals, over fifty products in registration and ten dosage form lines. Recognised as a national high-tech enterprise, a national enterprise technology centre and a national intellectual property demonstration enterprise.